Navigation Links
Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
Date:9/7/2012

THE WOODLANDS, Texas, Sept. 7, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, at 8:00 a.m. EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until October 11, 2012.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2020)... ... 05, 2020 , ... Smart Meter, a diabetes ... iGlucose® LTE Cat-M Cellular Connected Diabetes Blood Glucose Monitor and Remote Patient ... and broadest cellular connectivity available, to provide patients with seamless connectivity to their ...
(Date:4/23/2020)... ... April 22, 2020 , ... Across ... to protect themselves from COVID-19. Virginia has only been receiving 50% to 7.7% ... Association (FEMA). , As Governor Northam told the Virginia Mercury, “While we appreciate ...
(Date:4/22/2020)... ... April 21, 2020 , ... Ripple Science today ... clinical trial teams are working remotely and have paused patient visits, forcing teams ... continue their research during this uncertain time by giving research teams free access ...
(Date:4/7/2020)... ... April 06, 2020 , ... ... for the life sciences industry, has announced the release of at-home virtual learning ... top priority is the health and safety of our employees as we continue ...
Breaking Biology Technology:
(Date:5/21/2020)... ... 2020 , ... Catalent, the leading global provider of advanced ... and consumer health products, today announced that Jean-François Chaubard, Senior Director, Open Innovation ... Paris Virtual conference, which takes place on 28 – 29 May, 2020. , ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... North Shore and Greater Boston area, is pleased to announce a partnership with ... the busiest group practices in the area, Agility Orthopedics is focused on speeding ...
(Date:5/14/2020)... ... May 12, 2020 , ... ... that helps Life Science Manufacturers accurately and easily project contracted liabilities with ... of Gross-to-Net models by projecting discounts/rebates to Commercial and Government entities, Copay ...
Breaking Biology News(10 mins):